A system for mixing first and second solutions is provided. The system comprises: i) a syringe proportioner comprising a base adapted to receive first and second input syringes, and a gear assembly to drive a plunger of each of the input syringes to empty solution from each of the input syringes at a predetermined flow rate; ii) a channel comprising first and second inlets and a single outlet, the first and second inlets being adapted to fluidly couple respectively with first and second fluid expelling ends of each of the first and second input syringes, to receive solution from the first and second syringes; and iii) a static mixer comprising a fluid receiving end and a fluid discharging end, wherein the fluid receiving end is adapted to fluidly couple with the outlet of the channel and receive solution therefrom and the fluid discharging end is adapted to discharge fluid, said mixer comprising an internal geometry which provides mixing of a first and second solutions. The system is particularly useful for mixing solutions of different viscosities, for example, a cell suspension with a biomaterial solution to achieve effective mixing while minimizing sheer stress to retain cell viability.
B01F 23/45 - Mixing liquids with liquidsEmulsifying using flow mixing
B01F 25/421 - Static mixers in which the mixing is affected by moving the components jointly in changing directions, e.g. in tubes provided with baffles or obstructions by moving the components in a convoluted or labyrinthine path
B01F 25/432 - Mixing tubes, e.g. wherein the material is moved in a radial or partly reversed direction with means for dividing the material flow into separate sub-flows and for repositioning and recombining these sub-flowsCross-mixing, e.g. conducting the outer layer of the material nearer to the axis of the tube or vice-versa
B01F 25/4314 - Straight mixing tubes with baffles or obstructions that do not cause substantial pressure dropBaffles therefor with helical baffles
B01F 35/83 - Forming a predetermined ratio of the substances to be mixed by controlling the ratio of two or more flows, e.g. using flow sensing or flow controlling devices
The Trustees of Columbia University in the City of New York (USA)
McMaster University (USA)
Inventor
Chemali, Ephram
Preindl, Matthias
Abstract
An approach to control or monitoring of battery operation makes use of a recurrent neural network (RNN), which receives one or more battery attributes for a Lithium ion (Li-ion) battery, and determines, based on the received one or more battery attributes, a state-of-charge (SOC) estimate for the Li-ion battery.
G01R 31/382 - Arrangements for monitoring battery or accumulator variables, e.g. SoC
G06N 3/04 - Architecture, e.g. interconnection topology
G06N 3/0442 - Recurrent networks, e.g. Hopfield networks characterised by memory or gating, e.g. long short-term memory [LSTM] or gated recurrent units [GRU]
The disclosure relates to an in situ-gelling hydrogel composition based on functionalized zwitterionic polymers. The resulting hydrogels exhibit highly anti-fouling, anti-adhesive, and lubricating properties to enable the fabrication of bulk hydrogels or hydrogel-based coatings of relevance to biomedical applications.
Update systems and methods for a trained state of power (SOP) estimation model for a battery system of an electrified vehicle include obtaining real-time operation data of the battery system while deployed in the electrified vehicle, accessing the SOP estimation model, wherein the SOP estimation model is a machine learning model that is configured to estimate a SOP of the battery system based on a set of input parameters, identifying and obtaining, from a database configured to store lab data including test data of the battery system across a plurality of different operation conditions, a subset of the lab data that is most relevant to the real-time operation data of the battery system, updating the SOP estimation model via a low learning rate transfer learning process and using at least the subset of the lab data to obtain an updated SOP estimation model, and outputting the updated SOP estimation model.
A bar wound stator for an electric machine includes a stator core having a plurality of stator slots and a conductor assembly disposed in each slot. The conductor assembly includes a plurality of bar conductors having one or more first rectangular conductors with a first rectangular cross-section, and one or more split second rectangular conductors each having at least two split conductor members. Each split conductor member has a second rectangular cross-section smaller than the first rectangular cross-section, and each split conductor member is initially a straight bar member when inserted into the stator slot. The one or more split second rectangular conductors are configured to reduce AC copper loss of the electric machine.
H02K 3/28 - Layout of windings or of connections between windings
H02K 15/02 - Processes or apparatus specially adapted for manufacturing, assembling, maintaining or repairing of dynamo-electric machines of stator or rotor bodies
H02K 15/06 - Embedding prefabricated windings in the machines
H02K 15/085 - Forming windings by laying conductors into or around core parts by laying conductors into slotted stators
6.
TECHNIQUES FOR ESTIMATING BATTERY SYSTEM POWER CAPABILITY USING MACHINE LEARNING MODELS AND SEARCH ALGORITHMS
A state of power (SOP) estimation system for an electrified vehicle includes a battery system of the electrified vehicle and a control system configured to access a trained battery voltage estimation model configured to estimate a voltage of the battery system based on a set of input parameters including at least state of charge (SOC), temperature, and power or current, perform a search process to determine a final estimated SOP that causes the estimated voltage of the battery system to fall within a desired voltage range, and control the electrified vehicle based on the final estimated SOP of the battery system.
B60L 58/12 - Methods or circuit arrangements for monitoring or controlling batteries or fuel cells, specially adapted for electric vehicles for monitoring or controlling batteries responding to state of charge [SoC]
G05B 13/02 - Adaptive control systems, i.e. systems automatically adjusting themselves to have a performance which is optimum according to some preassigned criterion electric
7.
MULTIVALENT TRIDENT APTAMERS FOR MOLECULAR RECOGNITION, METHODS OF MAKING AND USES THEREOF
Multivalent trident aptamers comprising the general formula [A-SA]2 or 3-L-[SB-B] in which a central branched linker molecule (L) possesses 2 or 3 variable arms ([A-SA]2 or 3), and a root ([SB-B]), connected by a central carbon atom, to provide enhanced affinity and/or avidity with a target are described, as well as methods of making and using the multivalent trident aptamers are provided.
C12N 15/115 - Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith
A61K 9/00 - Medicinal preparations characterised by special physical form
A61K 31/7088 - Compounds having three or more nucleosides or nucleotides
A61P 31/16 - Antivirals for RNA viruses for influenza or rhinoviruses
C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids
C12Q 1/70 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving virus or bacteriophage
A pair of bioinks for printing a biosensor comprise: a first bioink being free of a crosslinking agent and comprising a scaffolding moiety and a biorecognition element for printing on a substrate; and a second bioink comprising a crosslinking agent for printing on and crosslinking the first bioink to form the biosensor.
Various embodiments are described herein for a system and method for condition monitoring and detecting and diagnosing faults in electromechanical or electrochemical systems and batteries using a frequency-domain statistical analysis framework. The method comprises receiving raw time-domain signals from one or more sensors monitoring the electromechanical or electrochemical system, applying a Short-Time Fourier Transform to convert the time-domain signals into a spectrogram, and segmenting the spectrogram into a plurality of frequency band segments. Each segment is independently analyzed using Principal Component Analysis based Multivariate Statistical Process Control, followed by statistical smoothing of the MSPC outputs. Fault conditions can be classified based on the smoothed statistical indicators, enabling accurate identification of deviations from baseline behavior.
H01M 10/48 - Accumulators combined with arrangements for measuring, testing or indicating the condition of cells, e.g. the level or density of the electrolyte
H02K 99/00 - Subject matter not provided for in other groups of this subclass
H02H 1/00 - Details of emergency protective circuit arrangements
C12Q 1/689 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for bacteria
11.
POROUS POLYETHER ETHER KETONE MEMBRANES, PREPARATION AND USES THEREOF
This disclosure relates fabricating membranes and in particular, to fabricating inert, high-performance asymmetric meso- and microporous poly(aryl ether ketones) (PAEK) membranes, such as poly ether-ether ketone (PEEK) membranes, methods of making and uses thereof. The method comprises combining one or more porogens selected from polyethylene glycol (PEG), polyethylene oxide (PEO), soluble PEG analogs, and soluble PEO analogs with the PAEK(s) in a suitable solvent. This disclosure also includes a method of preparing PEEK-OH.
C08J 9/26 - Working-up of macromolecular substances to porous or cellular articles or materialsAfter-treatment thereof by elimination of a solid phase from a macromolecular composition or article, e.g. leaching out
C08J 3/11 - Making solutions, dispersions, lattices or gels by other methods than by solution, emulsion or suspension polymerisation techniques in organic liquids from solid polymers
Described herein is a zwitterionic polymer-based coating that, when applied to an electrochemical biosensor, is capable of reducing fouling without compromising the current signal while also facilitating probe attachment.
The present invention discloses novel pentamidine analogues such as pentamidine analogs having the general formula:
The present invention discloses novel pentamidine analogues such as pentamidine analogs having the general formula:
The present invention discloses novel pentamidine analogues such as pentamidine analogs having the general formula:
wherein:
X is C, N, or —CH—CH—,
Y is Y1 when X is N, and Y is Y1 and Y2 when X is C, or —CH—CH—,
Y1, or Y1 and Y2 independently, are selected from H, hydroxyl, lower alkyl, lower alkoxy, halogen, nitro, amino, cyano or thiol, wherein the lower alkyl or alkoxy is optionally substituted with one or more of hydroxyl, halogen, nitro, amino, cyano, thiol, or a 5- or 6-membered aromatic or non-aromatic ring, optionally substituted with one or more of hydroxyl, lower alkyl, lower alkoxy, halogen, nitro, amino, cyano or thiol, wherein Y1 is not H when X is N; or
Y1 is a 5- or 6-membered aromatic or non-aromatic ring, optionally substituted with one or more groups selected from hydroxyl, lower alkyl, lower alkoxy, halogen, nitro, amino, cyano, carboxy, or thiol, and Y2 is H, if present; or
Y1 and Y2 together with X form a 5- to 8-membered hydrocarbon ring, optionally substituted with one or more groups selected from hydroxyl, lower alkyl, lower alkoxy, halogen, nitro, amino, cyano, carboxyl, or thiol;
Z is phenyl, optionally substituted with one or more groups selected from hydroxyl, lower alkyl, lower alkoxy, halogen, nitro, amino, cyano, carboxyl, or thiol; and
R1 to R4 are each independently H, hydroxyl, halogen, lower alkyl or lower alkoxy;
as well as related pentamidine analogs and their use to inhibit bacterial growth and treat bacterial infection.
C07C 257/18 - Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines with replacement of the other oxygen atom of the carboxyl group by nitrogen atoms, e.g. amidines having carbon atoms of amidino groups bound to carbon atoms of six-membered aromatic rings
A61K 31/40 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
A61K 31/4178 - 1,3-Diazoles not condensed and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
A61K 31/444 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. amrinone
A61K 31/451 - Non-condensed piperidines, e.g. piperocaine having a carbocyclic ring directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
A61K 31/7048 - Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin
C07D 211/34 - Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
C07D 213/78 - Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
C07D 233/64 - Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
C07D 295/155 - Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
14.
EXTRACELLULAR MATRIX-BASED HYDROGEL FORMULATION, METHODS OF MAKING AND USES THEREOF
This disclosure relates to the field of extracellular matrix-based hydrogels, and in particular, to hydrogel formulations comprising a decellularized extracellular matrix (dECM) and surface-modified cellulose nanofibers (CNFs) for precise tissue modeling and methods of making and uses thereof.
NONINVASIVE SYSTEMS AND METHODS FOR QUANTIFYING NEURAL SYNCHRONY IN THE COCHLEAR NERVE AND CORRELATING THE QUANTIFIED NEURAL SYNCHRONY WITH TEMPORAL RESOLUTION ACUITY AND SPEECH PERCEPTION OUTCOMES MEASURED IN QUIET AND IN NOISE
Disclosed herein are of systems, methods, and computer-program products of determining a peripheral neural synchrony value based on eCAPS and correlating the peripheral neural synchrony value with temporal resolution acuity and speech perception outcomes measured in quiet and in noise in the patient.
A protease-resistant ADAMTS13 mutant protein or nucleic acid encoding the ADAMTS13 mutant protein is provided. The ADAMTS13 mutant protein comprises a mammalian ADAMTS13 protein in which one or more protease cleavage sites within the protein are replaced with amino acid sequence that is resistant to protease cleavage, and the mutant protein retains von Willebrand factor (VWF)-cleaving activity. The protease-resistant ADAMTS13 mutant is useful as a thrombolytic agent to treat common thrombotic disorders, including stroke, myocardial infarction, venous thromboembolism, and rare microvascular thrombotic disorders like thrombotic thrombocytopenia purpura (TTP).
Example methods, compositions and structures are presented whereby sub-10-nm-thick strain-relieving Si1-xGex layers can be realized by Ge ion implantation, into, and selective oxidation of, Si(111) wafers. The resulting Ge-rich layers are fully strain relaxed via a network of misfit dislocations at the Si/Si1-xGe, interface, which do not propagate through the Si1-xGex film. The dislocation network has been found to coincide with a periodic variation in the composition at the Si/Si1-xGex interface and is believed to result from the defect-medicated diffusion of Si atoms from the Si substrate through the Si1-xGex layer to the above SiO2 layer. The epitaxial growth of GaAs on such ultra-thin substrates is demonstrated, presenting a promising approach for solving the long-standing challenge of local, monolithic integration of III-V optoelectronics on the Si platform.
H10H 20/818 - Bodies characterised by the crystal structures or orientations, e.g. polycrystalline, amorphous or porous within the light-emitting regions
H10H 20/824 - Materials of the light-emitting regions comprising only Group III-V materials, e.g. GaP
This disclosure provides a wearable electrochemical biosensor for detecting at least one target analyte in interstitial fluid of a subject, comprising, a microneedle array comprising a highly- crosslinked hydrogel polymer; at least one electrochemical chip comprising at least one transducer surface configured for generating a signal in the presence of the at least one target analyte; and a low crosslinked hydrogel polymer, wherein the low crosslinked hydrogel polymer is configured to couple the microneedle array with the at least one transducer surface of the electrochemical chip. Methods of making and use thereof are also disclosed.
A61B 5/1468 - Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value using chemical or electrochemical methods, e.g. by polarographic means
A61B 5/1473 - Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value using chemical or electrochemical methods, e.g. by polarographic means invasive, e.g. introduced into the body by a catheter
This disclosure relates to magnetic microgel beads, and in particular to magnetic microgel beads for biofunctionalization and methods of making and uses thereof, for example, in biosensing assays. In an embodiment, a magnetic microparticle comprising a magnetic nanoparticle encapsulated by a polymer hydrogel. In another embodiment, an assay for detecting the presence of a target analyte in a sample comprising a) the magnetic microparticle disclosed herein, wherein the biorecognition agent further comprises a reporter moiety; b) an electrochemical chip comprising a working electrode, a counter electrode and a reference electrode; and c) a capture probe functionalized on the working electrode; wherein binding of the biorecognition agent to the target analyte results in production of an electrochemical, electroluminescent or photoelectrochemical signal.
B60L 15/20 - Methods, circuits or devices for controlling the propulsion of electrically-propelled vehicles, e.g. their traction-motor speed, to achieve a desired performanceAdaptation of control equipment on electrically-propelled vehicles for remote actuation from a stationary place, from alternative parts of the vehicle or from alternative vehicles of the same vehicle train for control of the vehicle or its driving motor to achieve a desired performance, e.g. speed, torque, programmed variation of speed
H02J 7/00 - Circuit arrangements for charging or depolarising batteries or for supplying loads from batteries
H02M 7/5388 - Conversion of DC power input into AC power output without possibility of reversal by static converters using discharge tubes with control electrode or semiconductor devices with control electrode using devices of a triode or transistor type requiring continuous application of a control signal using semiconductor devices only, e.g. single switched pulse inverters in a bridge configuration with asymmetrical configuration of switches
H02P 25/092 - Converters specially adapted for controlling reluctance motors
H02P 25/098 - Arrangements for reducing torque ripple
22.
PORTABLE ELECTROCHEMICAL DEVICE FOR BIOSENSING AND METHODS OF MAKING AND USES THEREOF
A portable biosensing readout system for analyzing a sample is described herein. The system include a biosensor comprising a working electrode, a reference electrode and a counter electrode. The system also includes a core potentiostat circuit coupled to the biosensor, the core potentiostat circuit having one or more amplifiers configured to inject an excitation signal into the biosensor; isolate the reference electrode; and convert current of an output signal from the biosensor to voltage. The system also includes a microcontroller unit in communication with the core potentiostat circuit, the microcontroller unit being configured to: generate various different types of excitation signals that are transmitted to the core potentiostat circuit and, subsequently, to the biosensor; receive the output signal from the core potentiostat circuit; and communicate the output signal to an external computing device. The system also includes a peripheral instrument in communication with the microcontroller unit for processing the sample.
G01N 27/30 - Electrodes, e.g. test electrodesHalf-cells
G01N 33/549 - ImmunoassayBiospecific binding assayMaterials therefor with an insoluble carrier for immobilising immunochemicals the carrier being organic with antigen or antibody entrapped within the carrier
23.
DETERMINATION OF SPATIAL DISTRIBUTIONS OF RADIONUCLIDES IN TISSUE SAMPLES VIA MASS SPECTROMETRY IMAGING OF METAL ISOTOPES
An antithrombotic surface-modified biomaterial is provided comprising a biomaterial substrate coated with a polymerizable dopamine-containing bioadhesive to which is attached one or more antithrombotic agents. A method of preparing the surface-modified biomaterial is also provided. The surface-modified biomaterial is beneficial for use in blood-contacting medical devices such as catheters, dialyzers and blood oxygenators to prevent or minimize the occurrence of thrombosis on the surface thereof.
A61L 33/00 - Antithrombogenic treatment of surgical articles, e.g. sutures, catheters, prostheses, or of articles for the manipulation or conditioning of bloodMaterials for such treatment
25.
DETERMINATION OF SPATIAL DISTRIBUTIONS OF PHARMACEUTICALS IN TISSUE SAMPLES VIA MASS SPECTROMETRY IMAGING OF METAL ISOTOPES
Systems and methods are disclosed for determining the spatial distributions of radionuclides in tissue samples via mass spectrometry imaging. After administration of a radiopharmaceutical that contains a radionuclide, a mass spectrometry imaging system, such as an imaging mass cytometer or a multiplexed ion beam imaging system, is employed to interrogate a tissue sample to obtain a dataset. The radiopharmaceutical includes, or generates via radioactive decay of the radionuclide, a metal isotope detectable by the mass spectrometry imaging system. The dataset is processed to determine a spatial distribution of the metal isotope within the tissue sample, thereby characterizing the spatial distribution of the radionuclide delivered within the tissue sample. The tissue sample may be stained with a biomarker reagent that includes an additional metal isotope attached to a biomarker ligand, enabling the spatially multiplexed and co-registered analysis. The present methods can be adapted to infer and assess localization of non-radioactive pharmaceuticals.
G01N 33/60 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving labelled substances involving radioactive labelled substances
A61K 51/12 - Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes
26.
A CORE-SHELL CATALYST, METHODS OF MAKING AND USES THEREOF
xx; and a shell comprising iridium, methods of preparing core-shell particles, and uses thereof, such as a catalyst in an oxygen evolution reaction (OER).
A method of determining a phase correction to apply to a corrective element, comprising the steps of: acquiring low-resolution images; determining pixel intensity values in the low-resolution images; adding pixels one at a time in order of decreasing intensity; back-propagating each image to a pupil plane to obtain an estimate; and measuring a coupling efficiency to phase points to determine an optimum phase.
G02B 27/00 - Optical systems or apparatus not provided for by any of the groups ,
H04B 10/073 - Arrangements for monitoring or testing transmission systemsArrangements for fault measurement of transmission systems using an out-of-service signal
H04B 10/112 - Line-of-sight transmission over an extended range
28.
DIE CASTING ALUMINUM ALLOYS FOR STRUCTURAL AND NON-STRUCTURAL NEAR SHAPED COMPONENTS, AND METHODS FOR PRODUCING SAME
This disclosure provides aluminum alloys for casting near-net shaped components comprising zinc (Zn), magnesium (Mg), iron (Fe), and cerium (Ce) as primary alloying elements, and silicon (Si), nickel (Ni), cobalt (Co), copper (Cu), manganese (Mn), titanium (Ti), boron (B), vanadium (V), zirconium (Zr) scandium (Sc), chromium (Cr), strontium (Sr), sodium (Na), beryllium (Be), and molybdenum (Mo) as possible minor alloying elements. Methods for production of the aluminum alloys, such as pressure assisted die casting and heat treatment, are also disclosed herein.
C22C 21/10 - Alloys based on aluminium with zinc as the next major constituent
C22F 1/053 - Changing the physical structure of non-ferrous metals or alloys by heat treatment or by hot or cold working of aluminium or alloys based thereon of alloys with zinc as the next major constituent
The present disclosure relates to a multi-panel system and a method of producing thereof. The construction element comprises a first panel having a first end and an opposed second end; a second panel spaced apart from the first panel, the second panel having a first end and an opposed second end; a spacing medium placed between the first and second panels, and adhering to each of the first and second panels; and at least one structural member integrally formed in at least one of the panels, and extending from the first end to the second end of the least one panels. At least one structural member is provided for bearing external force, and the first panel does not contact the second panel to prevent thermal bridging.
E04C 2/34 - Building elements of relatively thin form for the construction of parts of buildings, e.g. sheet materials, slabs, or panels characterised by the shape or structure composed of two or more spaced sheet-like parts
E04C 2/52 - Building elements of relatively thin form for the construction of parts of buildings, e.g. sheet materials, slabs, or panels characterised by the shape or structure with special adaptations for auxiliary purposes, e.g. serving for locating conduits
30.
High-Throughput Methods of Synthesizing Biofunctional Microparticles and Related Compositions
Described herein is a high-throughput method of synthesizing biofunctional microparticles. In aspects, the method comprises casting biofunctional microparticle precursors onto a microporous template to form microparticles, wherein the template comprises a removable film; and removing the film to liberate the microparticles. Also described herein is a sprayable microgel and related methods.
TOYOTA MOTOR ENGINEERING & MANUFACTURING NORTH AMERICA, INC. (USA)
TOYOTA JIDOSHA KABUSHIKI KAISHA (Japan)
MCMASTER UNIVERSITY (Canada)
Inventor
Zeiynali Farid, Yashar
Yang, Hao
Ucar, Seyhan
Oguchi, Kentaro
Abstract
Systems and methods are provided for determining a start time and severity value associated with the roadway incident to provide traffic management instructions. The system may, for example, receive sensor data from a vehicle at a location associated with a roadway incident. The system can determine a traffic flow profile for the location, where the traffic flow profile identifies characteristics of the roadway incident that match characteristics of the traffic flow profile. Based on the traffic flow profile, the system may determine a severity value for the roadway incident and calculate a start time of the roadway incident. The start time may correspond with the traffic flow profile for the location in view of the severity value.
G08G 1/015 - Detecting movement of traffic to be counted or controlled with provision for distinguishing between motor cars and cycles
G06T 7/73 - Determining position or orientation of objects or cameras using feature-based methods
G06V 20/58 - Recognition of moving objects or obstacles, e.g. vehicles or pedestriansRecognition of traffic objects, e.g. traffic signs, traffic lights or roads
G08G 1/01 - Detecting movement of traffic to be counted or controlled
G08G 1/017 - Detecting movement of traffic to be counted or controlled identifying vehicles
G08G 1/04 - Detecting movement of traffic to be counted or controlled using optical or ultrasonic detectors
32.
PROGNOSTIC METHOD FOR ACUTE MYELOID LEUKEMIA (AML) AND NON-CANONICAL AML REGENERATION
This disclosure relates to methods for identifying Acute Myeloid Leukemia (AML) regeneration enriched cells (RECs) in a patient sample, as well as methods for purifying RECs and for generating RECs, such as for use in an assay for screening therapeutic agents. Also described herein are methods of predicting the prognosis, risk of relapse and/or treatment response in patients with AML, as well as methods for selecting patients with AML for treatment, and methods for treating patients with AML. Further provided are kits for use in the methods described herein.
C12Q 1/02 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving viable microorganisms
G01N 15/01 - Investigating characteristics of particlesInvestigating permeability, pore-volume or surface-area of porous materials specially adapted for biological cells, e.g. blood cells
G01N 15/14 - Optical investigation techniques, e.g. flow cytometry
G01N 15/149 - Optical investigation techniques, e.g. flow cytometry specially adapted for sorting particles, e.g. by their size or optical properties
G01N 33/48 - Biological material, e.g. blood, urineHaemocytometers
G01N 33/543 - ImmunoassayBiospecific binding assayMaterials therefor with an insoluble carrier for immobilising immunochemicals
A61K 31/7068 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
G16B 25/10 - Gene or protein expression profilingExpression-ratio estimation or normalisation
The present disclosure provides a compound comprising a radiolabeling moiety, a targeting moiety, and a DNA intercalating agent and complexes thereof For example, the present disclosure provides a compound of Formula I or a pharmaceutically acceptable salt and/or solvate thereof. Methods of making and uses thereof, such as cancer theranostic applications, are also included. (I)
C07K 5/037 - Peptides having up to four amino acids in a fully defined sequenceDerivatives thereof containing at least one abnormal peptide link the abnormal link being formed by the side chain of an alpha-amino acid, e.g. gamma-Glu, epsilon-Lys, glutathione
C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids
The present application describes processes for depositing a material comprising elemental germanium, comprising use of a germanium-containing precursor compound in combination with a base-free hydroborane, hydrosilane, hydrostannane, or hydroalane co-reactant.
Copper, silver and gold fluorinated alkoxide complexes such as complexes having a structure represented by the general formula (I) are described:, and multimers thereof and/or crystalline forms thereof as well as uses thereof, such as in processes to prepare materials, films and/or structures comprising copper, silver or gold using, processes including atomic layer deposition and chemical vapor deposition processes.
C23C 16/06 - Chemical coating by decomposition of gaseous compounds, without leaving reaction products of surface material in the coating, i.e. chemical vapour deposition [CVD] processes characterised by the deposition of metallic material
An electrochemical cell housing, electro-amalgamation apparatus and method for separating product and non-product lanthanides is provided. The electro-amalgamation apparatus comprises an electrochemical cell with an electrochemical cell housing, where the cell housing comprises an inlet for introducing a substrate into the electrochemical cell for making at least one product. The electrochemical cell comprises an electrochemical cell solution that is held within the cavity and that comprises at least two layers that each have different densities. The electro-amalgamation apparatus comprises an anode element that is at least partially disposed within a lower density layer of the at least two layers, a cathode element that is at least partially disposed within a higher density layer, and a drainage assembly that is coupled to the electrochemical cell for collecting the lower density layer of the at least two layers.
The present disclosure relates to methods for determining concentration of a lysine analog antifibrinolytic agent in a sample. Also provided are kits comprising (a) a composition comprising a fluorescently labeled inactive plasminogen variant and a fluorescence quencher labeled fibrin-degradation product (FDP) and (b) a lysine analog antifibrinolytic agent standard and methods of use thereof.
The present disclosure relates to the field of protein-based materials, and in particular, to a protein eutectogel prepared with natural deep eutectic solvents and one or more plant proteind, methods of making and uses thereof.
B33Y 70/00 - Materials specially adapted for additive manufacturing
C07K 14/415 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from plants
C08J 3/11 - Making solutions, dispersions, lattices or gels by other methods than by solution, emulsion or suspension polymerisation techniques in organic liquids from solid polymers
C12N 5/00 - Undifferentiated human, animal or plant cells, e.g. cell linesTissuesCultivation or maintenance thereofCulture media therefor
39.
BIOMOLECULE-BASED WRINKLED NETWORK AND RELATED METHODS
In at least one embodiment, a DC-DC power converter comprises a primary circuit coupled to a DC input voltage, a secondary circuit coupled to a DC output voltage, and a transformer isolating the primary from the secondary circuit. The primary circuit comprises a first and second circuit branch. The first circuit branch comprises a plurality of switches, a diode, and a reconfiguration switch. The second circuit branch comprises a plurality of switches, and a plurality of diodes. The reconfiguration switch is operable to switch the primary circuit between a first mode and a second mode, wherein the primary circuit operates as a full-bridge circuit in the first mode and the primary circuit operates as a half-bridge circuit in the second mode.
H02M 3/335 - Conversion of DC power input into DC power output with intermediate conversion into AC by static converters using discharge tubes with control electrode or semiconductor devices with control electrode to produce the intermediate AC using devices of a triode or a transistor type requiring continuous application of a control signal using semiconductor devices only
This disclosure relates to the field of 3D extrusion bioprinting, and in particular, to compositions of bioinks including components that are typically non-extrudable or present low printability. The present bioink comprises a rheology modifier, such as a partially crosslinked polyacrylic acid, a crosslinking polymer, and, optionally, one or more additives. The bioink provides for the use of synthetic crosslinking polymers as well as modified or unmodified biopolymers, and exhibits good printability.
C12N 5/00 - Undifferentiated human, animal or plant cells, e.g. cell linesTissuesCultivation or maintenance thereofCulture media therefor
B29C 64/118 - Processes of additive manufacturing using only liquids or viscous materials, e.g. depositing a continuous bead of viscous material using filamentary material being melted, e.g. fused deposition modelling [FDM]
B29K 105/00 - Condition, form or state of moulded material
B29K 105/24 - Condition, form or state of moulded material cross-linked or vulcanised
The present disclosure relates to solid-state sensors that exploit a unique sensing mechanism which amplifies the response of ion-selective membranes (ISM) several fold. In the presence of the analyte, such as lead, the binding sites within the membrane bind with the analyte modulating the interactions between the binding sites and the chemiresi stive film. This competitive binding provides a higher sensitivity when compared with conventional ion-selective electrode configurations. It also differs from a simple chemiresistor covered with an ISM because the reference electrode can be eliminated. The impact of these interactions on the conductivity of the film can also be maximized by its surface treatment, ultimately achieving a lower level of detection than possible with potentiometric methods. Sensors developed using this design may be employed as aqueous continuous in situ ion sensors to detect harmful levels of analytes in surface, drinking, or wastewater.
G01N 27/12 - Investigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating impedance by investigating resistance of a solid body in dependence upon absorption of a fluidInvestigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating impedance by investigating resistance of a solid body in dependence upon reaction with a fluid
43.
ERINACINE A AND ANALOGS THEREOF FOR THERAPEUTIC USE
The present application includes compounds of Formula I and II, compositions comprising these compounds and uses thereof, in particular for treatment of central nervous system (CNS) or peripheral nervous system (PNS) diseases, disorders or conditions, and for promoting or improving wound healing. (Formula I/II)
C07C 235/40 - Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of rings other than six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
A61K 31/00 - Medicinal preparations containing organic active ingredients
A61K 31/27 - Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, e.g. meprobamate, carbachol, neostigmine
A61K 31/133 - Amines, e.g. amantadine having hydroxy groups, e.g. sphingosine
A61K 31/235 - Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
A61K 31/343 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
A61K 31/423 - Oxazoles condensed with carbocyclic rings
A61K 31/505 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim
A61K 31/704 - Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin, digitoxin
A61K 31/4402 - Non-condensed pyridinesHydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
A61K 31/4409 - Non-condensed pyridinesHydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
A61K 31/7056 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
A61P 25/00 - Drugs for disorders of the nervous system
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
C07C 215/42 - Compounds containing amino and hydroxy groups bound to the same carbon skeleton having amino groups or hydroxy groups bound to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
C07C 233/72 - Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom of an unsaturated carbon skeleton containing rings other than six-membered aromatic rings
C07C 235/68 - Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having the nitrogen atom of at least one of the carboxamide groups bound to an acyclic carbon atom and to a carbon atom of a six-membered aromatic ring wherein at least one ortho-hydrogen atom has been replaced
C07C 237/24 - Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a ring other than a six-membered aromatic ring of the carbon skeleton
C07C 307/02 - Monoamides of sulfuric acids or esters thereof, e.g. sulfamic acids
C07D 203/04 - Heterocyclic compounds containing three-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
C07D 263/56 - BenzoxazolesHydrogenated benzoxazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
C07D 307/79 - Benzo [b] furansHydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
C07H 15/24 - Condensed ring systems having three or more rings
44.
SYSTEMS AND METHODS FOR DC-DC POWER CONVERTER TOPOLOGIES
Systems and methods for providing DC-DC power converter topologies are described. In at least one embodiment, a DC-DC power converter comprises a primary sub-circuit coupled to a fixed or variable DC input voltage, a first secondary sub-circuit and a second secondary sub-circuit, a transformer isolating the primary sub-circuit from the first and the second secondary sub-circuits, the transformer comprising a predetermined number of turns, the first and the second secondary sub-circuits being configurable in a series mode and a parallel mode by switching configurations of a first, second and third transition switch, and the first and the second secondary sub-circuits providing an output charging voltage and an output charging current for charging an external device.
An endoscope tracker that measures the endoscope’s motion using a pair of trackballs and two video cameras is provided. The trackballs measure real-time changes in the scope’s position and rotation during an endoscopic procedure. The cameras detect scale lines on the scope’s surface to correct accumulated trackball measurement errors. A dual modality tracking method measures the motion of the endoscope’s insertion tube in real time, including insertion length, rotation angle, and their velocities. Optical trackballs measure the endoscope insertion tube’s motion, and cameras correct cumulative errors. A purely optical endoscope tracker that measures the endoscope’s motion is also provided, using video cameras and software that processes the images obtained from the video cameras to determine how the endoscope moves over time.
A61B 1/05 - Instruments for performing medical examinations of the interior of cavities or tubes of the body by visual or photographical inspection, e.g. endoscopesIlluminating arrangements therefor combined with photographic or television appliances characterised by the image sensor, e.g. camera, being in the distal end portion
A61B 1/06 - Instruments for performing medical examinations of the interior of cavities or tubes of the body by visual or photographical inspection, e.g. endoscopesIlluminating arrangements therefor with illuminating arrangements
A61B 34/20 - Surgical navigation systemsDevices for tracking or guiding surgical instruments, e.g. for frameless stereotaxis
An impact protection structure, including a sheet formed of a plurality of polygonal cells adjacent one another, the plurality of polygonal cells including a plurality of hexagonal cells, the plurality of polygonal cells including at least one pentagonal cell and at least one heptagonal cell to accommodate a generally domed shape in the sheet with a reduction in a distortion of a regular shape of the plurality of hexagonal cells.
B32B 3/02 - Layered products comprising a layer with external or internal discontinuities or unevennesses, or a layer of non-planar shapeLayered products comprising a layer having particular features of form characterised by features of form at particular places, e.g. in edge regions
47.
SCALABLE FABRICATION OF A SELF-ASSEMBLED CELL SHEET AND USES THEREOF
This disclosure relates to methods of fabricating self-assembled 3D cell sheets. In one embodiment, the cell sheets are formed by seeding cells to a monolayer density of at least 65% with a culture medium on to a substantially flat substrate having low surface energy and incubating cells on the substrate under time and temperature conditions to form a cell sheet.
This disclosure relates to the field of lipidomics, and in particular, to a novel derivatization strategy for quantitative lipid methylation and uses thereof. Further, this disclosure relates to use of phospholipid biomarkers for assessing and monitoring Omega-3 Index (O3I), including methods and uses thereof.
In some cases, flood risk quantification computing systems and methods are computationally intensive and in some cases are inaccurate. A flood risk computing system and method are provided that quantifies a flood vulnerability within a specified area of interest, irrespective of flood event characteristics; estimates and maps a flood hazard probability; integrates the flood vulnerability and the flood hazard probability to quantify a flood risk; and develops a rapid flood risk software tool, stored in the memory, to directly quantify flood risk characteristics using deep learning. The rapid flood risk tool uses a plurality of hierarchical deep neural networks.
G01F 1/002 - Measuring the volume flow or mass flow of fluid or fluent solid material wherein the fluid passes through a meter in a continuous flow wherein the flow is in an open channel
A method of treating a wound is provided comprising the administration of a therapeutically effective amount of a bicarbonate to a wound. Bicarbonate has been found to facilitate wound healing by promoting at least one of cell proliferation, collagen production and/or fibronectin production, or treating undesirable inflammation, within a wound.
The Governing Council of the University of Toronto (Canada)
McMaster University (Canada)
Inventor
Moffat, Jason
Montenegro Burke, Jose Rafael
Singh, Sheila K.
Gwynne, William D.
Venugopal, Chitra
Abstract
The present disclosure relates to the treatment of a myc-amplified cancer using a DHODH inhibitor. Also disclosed herein are combination therapies, compositions and kits for the treatment of a myc-amplified cancer comprising a DHODH inhibitor.
Multivalent tetrameric and octameric aptamers comprising a G-quadruplex comprised of monomeric aptamer subunits having the general formula A – SA – [G]n – SB – B in which self-assembly of a G-tetrad linkage structure connects the aptameric arms in parallel orientation to provide enhanced affinity and/or avidity with a target are described, as well as methods of making and using the multivalent aptamers are provided.
C12N 15/115 - Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith
A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
C12N 15/11 - DNA or RNA fragmentsModified forms thereof
C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids
C12Q 1/6804 - Nucleic acid analysis using immunogens
G01N 33/543 - ImmunoassayBiospecific binding assayMaterials therefor with an insoluble carrier for immobilising immunochemicals
A co-planar transformer is provided. A dual-active bridge converter comprising the co¬ planar transformer is also provided. The co-planar transformer comprises a printed circuit board with a plurality of primary windings and a plurality of secondary windings. The number of primary winding turns is equal to the number of secondary winding turns. The plurality of primary windings and the plurality of secondary windings are provided on the same printed circuit board in an interleaving configuration, wherein the interleaving is provided horizontally across the printed circuit board. Other embodiments of co-planar transformers include two or more such printed circuit boards with interleaved plurality of primary and secondary windings.
An endoscope tracker that measures the endoscope's motion using a pair of trackballs and two video cameras is provided. The trackballs measure real-time changes in the scope's position and rotation during an endoscopic procedure. The cameras detect scale lines on the scope's surface to correct accumulated trackball measurement errors. A dual modality tracking method measures the motion of the endoscope's insertion tube in real time, including insertion length, rotation angle, and their velocities. Optical trackballs measure the endoscope insertion tube's motion, and cameras correct cumulative errors. A purely optical endoscope tracker that measures the endoscope's motion is also provided, using video cameras and software that processes the images obtained from the video cameras to determine how the endoscope moves over time.
A61B 1/00 - Instruments for performing medical examinations of the interior of cavities or tubes of the body by visual or photographical inspection, e.g. endoscopesIlluminating arrangements therefor
A61B 1/05 - Instruments for performing medical examinations of the interior of cavities or tubes of the body by visual or photographical inspection, e.g. endoscopesIlluminating arrangements therefor combined with photographic or television appliances characterised by the image sensor, e.g. camera, being in the distal end portion
A61B 34/20 - Surgical navigation systemsDevices for tracking or guiding surgical instruments, e.g. for frameless stereotaxis
G06T 3/40 - Scaling of whole images or parts thereof, e.g. expanding or contracting
A distributed feedback (DFB) semiconductor laser assembly is disclosed. The DFB laser assembly includes a substrate extending along a longitudinal direction, a first electrode layer disposed on a first side surface thereof, an active region layer disposed on a second side surface thereof opposite the first side surface, and a spacer layer disposed on the active region layer. A ridge extends away from the active region layer and along the longitudinal direction. The DFB laser assembly also includes a grating layer integrated between the active region layer and the ridge, the grating layer including a plurality of sampled gratings along the longitudinal direction, and a second electrode layer electrically coupled to the first electrode layer, the second electrode layer comprising independent electrode sections disposed on the top ridge surface and each ridge side surface.
H01S 5/12 - Construction or shape of the optical resonator the resonator having a periodic structure, e.g. in distributed feedback [DFB] lasers
H01S 5/183 - Surface-emitting [SE] lasers, e.g. having both horizontal and vertical cavities having only vertical cavities, e.g. vertical cavity surface-emitting lasers [VCSEL]
H01S 5/30 - Structure or shape of the active regionMaterials used for the active region
57.
VEHICLE PARTS WITH INTEGRATED PHOTOVOLTAIC ELEMENTS, VEHICLES CONTAINING SUCH VEHICLE PARTS, AND METHODS OF MAKING SUCH VEHICLE PARTS
A vehicle part with at least one integrated photovoltaic element includes a part body, at least one area of a barrier layer disposed on at least a portion of the surface of the part body; and at least one photovoltaic element disposed over an area of the barrier layer. Paint covers the portions of the surface of the part body surrounding the photovoltaic elements. A method of making a vehicle part having at least one integrated photovoltaic element includes applying at least one area of a barrier layer on at least a portion of the surface of the part and applying at least one photovoltaic element over an area of the barrier layer. A protective layer is applied over the surface of the photovoltaic element, the surface of the part is painted, and the protective layer can then be removed to expose the photovoltaic element.
This disclosure relates to a method of identifying or producing an aptamer capable of binding to at least two target analyte variants, the method comprises generating a mixture of systematic evolution of ligands by exponential enrichment (SELEX)-selected aptamers by at least one-round of SELEX with a SELEX-compatible aptamer pool against the at least two target analyte variants in parallel or sequentially, sequencing the mixture of SELEX-selected aptamers that form complexes with each of the at least two target analyte variants by high-throughput sequencing, aligning the mixture of SELEX-selected aptamers that form complexes with each of the at least two target analyte variants by sequence alignment analysis, and identifying or producing the aptamer capable of binding to the at least two target analyte variants. Aptamers thereof and uses of the aptamers thereof are also disclosed.
C12N 15/115 - Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith
C12N 15/10 - Processes for the isolation, preparation or purification of DNA or RNA
C40B 30/04 - Methods of screening libraries by measuring the ability to specifically bind a target molecule, e.g. antibody-antigen binding, receptor-ligand binding
G01N 33/569 - ImmunoassayBiospecific binding assayMaterials therefor for microorganisms, e.g. protozoa, bacteria, viruses
59.
SYSTEMS AND METHODS FOR ASSESSING AORTIC VALVE CALCIFICATION USING CONTRAST-ENHANCED COMPUTED TOMOGRAPHY (CT)
Described is a method for assessing aortic valve calcification using contrast-enhanced CT. The method comprises: receiving CT images of the aortic valve; pre-processing received images to have a field of view focused on an aortic root corresponding to the aortic valve; implementing a fast-marching method for the pre-processed images to segment the aortic valve from surrounding tissue to generate an aortic root model; determining multiple principal axes and multiple landmark points based on the pre-processed images and the aortic root model to define a local coordinate system relative to leaflets of the aortic valve; generating a calcification model based on the pre-processed images and aortic root model by iteratively changing an initial estimate of calcific HU threshold until a minimum false positive rate FPR criterion is reached; and generating an indicator quantifying calcification of the aortic valve based on the calcification model, the principal axes and the landmark points.
A61B 6/50 - Apparatus or devices for radiation diagnosisApparatus or devices for radiation diagnosis combined with radiation therapy equipment specially adapted for specific body partsApparatus or devices for radiation diagnosisApparatus or devices for radiation diagnosis combined with radiation therapy equipment specially adapted for specific clinical applications
A61B 6/00 - Apparatus or devices for radiation diagnosisApparatus or devices for radiation diagnosis combined with radiation therapy equipment
The present disclosure relates generally to the field of cancer immunotherapy. More particularly, the present disclosure relates to multivalent antibody recruitment molecules and methods of treating cancer using same.
C07K 5/02 - Peptides having up to four amino acids in a fully defined sequenceDerivatives thereof containing at least one abnormal peptide link
C07K 7/06 - Linear peptides containing only normal peptide links having 5 to 11 amino acids
C07K 7/56 - Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring the cyclisation not occurring through 2,4-diamino-butanoic acid
A trivalent transgene that encodes a viral surface glycoprotein component, a viral nucleoprotein component and a viral RNA polymerase component is provided. Vaccines incorporating the trivalent transgene are also provided, along with methods of vaccinating mammals to protect against viral infection.
G01N 27/26 - Investigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating electrochemical variablesInvestigating or analysing materials by the use of electric, electrochemical, or magnetic means by using electrolysis or electrophoresis
Kdd d < about 300 pM; wherein the multimeric aptamer is configured to bind to the surface of the working electrode, and wherein the biosensor system is configured to operate in a wash-free and single-pot format.
G01N 27/26 - Investigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating electrochemical variablesInvestigating or analysing materials by the use of electric, electrochemical, or magnetic means by using electrolysis or electrophoresis
In some cases, flood risk quantification computing systems and methods are computationally intensive and in some cases are inaccurate. A flood risk computing system and method are provided that quantifies a flood vulnerability within a specified area of interest, irrespective of flood event characteristics; estimates and maps a flood hazard probability; integrates the flood vulnerability and the flood hazard probability to quantify a flood risk; and develops a rapid flood risk software tool, stored in the memory, to directly quantify flood risk characteristics using deep learning. The rapid flood risk took using a plurality of hierarchical deep neural networks.
G06N 3/0442 - Recurrent networks, e.g. Hopfield networks characterised by memory or gating, e.g. long short-term memory [LSTM] or gated recurrent units [GRU]
G06N 3/084 - Backpropagation, e.g. using gradient descent
65.
SYSTEMS AND METHODS FOR DC-DC POWER CONVERTER TOPOLOGIES
Systems and methods for providing DC-DC power converter topologies are described. In at least one embodiment, a DC-DC power converter comprises a primary sub-circuit coupled to a fixed or variable DC input voltage, a first secondary sub-circuit and a second secondary sub-circuit, a transformer isolating the primary sub-circuit from the first and the second secondary sub-circuits, the transformer comprising a predetermined number of turns, the first and the second secondary sub-circuits being configurable in a series mode and a parallel mode by switching configurations of a first, second and third transition switch, and the first and the second secondary sub-circuits providing an output charging voltage and an output charging current for charging an external device.
H02M 3/335 - Conversion of DC power input into DC power output with intermediate conversion into AC by static converters using discharge tubes with control electrode or semiconductor devices with control electrode to produce the intermediate AC using devices of a triode or a transistor type requiring continuous application of a control signal using semiconductor devices only
H02M 3/00 - Conversion of DC power input into DC power output
66.
Quality Control Materials for Cardiac Troponin Testing
A method for the preparation of a cardiac troponin quality control sample of a mammal to determine the accuracy and/or precision of a cardiac troponin assay over time is provided. The method comprises the steps of: i) preparing a cardiac troponin concentrate from a pool of biological samples obtained from a population of the mammal having a troponin concentration of greater than 75% of an upper analytical limit of the assay; ii) obtaining a cardiac troponin base material comprising whole blood, plasma or serum of the mammal which is interference-free and disease-free; and iii) combining a quantity of the troponin concentrate with the base material to yield a quality control sample having a target concentration. Quality control samples may be provided in kits which provide a set of samples having particular concentrations which essentially correspond with lower detectable limits of an assay, upper limits of normal, as well as concentrations which define risk stratification cutoffs and other diagnostic cutoffs.
G01N 33/96 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving blood or serum control standard
67.
SCALABLE FABRICATION OF A SELF-ASSEMBLED CELL SHEET AND USES THEREOF
This disclosure relates to methods of fabricating self-assembled 3D cell sheets. In one embodiment, the cell sheets are formed by seeding cells to a monolayer density of at least 65% with a culture medium on to a substantially flat substrate having low surface energy and incubating cells on the substrate under time and temperature conditions to form a cell sheet.
Described herein is a functionalized biological membrane comprising an endogenous bilayer and one or more modifying protein molecules embedded therein or attached thereto. Also described herein is a method of preparing a functionalized biological membrane comprising one or more modifying protein molecules embedded therein or attached thereto, and methods of use and uses of said functionalized biological membranes.
A system, method and computer program product for evaluating a multi-label classification machine learning model. A model labelled dataset is received from the model and includes a plurality of data elements each labelled with zero or more model predicted labels of q potential classes. A multi-label confusion matrix is defined to include q +1 rows with q rows for true labels and 1 row for no true label and q +1 columns with q columns for predicted labels and 1 column for no predicted label. The matrix is populated by comparing the model labelled dataset with a true labelled dataset. At least one performance metric is calculated from the populated multi-label confusion matrix.
An LLC resonant converter is provided. The LLC resonant converter includes a primary sub-circuit coupled to a direct-current (DC) input voltage and a first secondary sub-circuit and a second secondary sub-circuit. The primary sub-circuit includes a resonant tank, that includes a combination of a resonant inductor, a resonant capacitor and a magnetizing inductor. The LLC resonant converter also includes a first transformer isolating the primary sub-circuit from the first secondary sub-circuit and a second transformer isolating the primary sub-circuit from the second secondary sub-circuit. The first and the second secondary sub-circuits are configurable in a series mode and a parallel mode by switching configurations of a plurality of transition switches, and the first and the second secondary sub-circuits provide an output charging voltage and an output charging current for charging an external device. A charging station comprising one or more charging poles, with each charging pole comprising one of more LLC resonant converter modules is also disclosed.
B60L 53/30 - Constructional details of charging stations
H02M 3/335 - Conversion of DC power input into DC power output with intermediate conversion into AC by static converters using discharge tubes with control electrode or semiconductor devices with control electrode to produce the intermediate AC using devices of a triode or a transistor type requiring continuous application of a control signal using semiconductor devices only
71.
PRODUCTS AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF HEPARIN-INDUCED THROMBOCYTOPENIA
Provided herein are wildtype and mutant single chain variable fragments (scFvs) of the anti-PF4/heparin monoclonal antibody KKO, and variants thereof which are useful for distinguishing between platelet-activating (pathogenic) and non-activating (non-pathogenic) anti-PF4/heparin antibodies. Also provided herein are uses of the scFvs in methods for identifying patients with pathogenic anti-PF4/heparin antibodies, and for diagnosing and treating heparin-induced thrombocytopenia (HIT).
C07K 16/24 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
A61K 39/00 - Medicinal preparations containing antigens or antibodies
An impact protection structure, including a sheet formed of a plurality of polygonal cells adjacent one another, the plurality of polygonal cells including a plurality of hexagonal cells, the plurality of polygonal cells including at least one pentagonal cell and at least one heptagonal cell to accommodate a generally domed shape in the sheet with a reduction in a distortion of a regular shape of the plurality of hexagonal cells.
F16F 1/374 - Springs made of plastics, e.g. rubberSprings made of material having high internal friction characterised by having a particular shape having a spherical or the like shape
F16F 1/377 - Springs made of plastics, e.g. rubberSprings made of material having high internal friction characterised by having a particular shape having holes or openings
A method of treating or inhibiting the development of fibrosis in a subject is provided. The method comprises administering to the subject a therapeutically effective amount of an entity that disrupts the interaction between activated alpha 2-macroglobulin (α2M*) and cell surface 78 kDa glucose regulated protein csGRP78. In one embodiment, administration of novel peptides that block activated α2-macroglobulin (α2M*) interaction with csGRP78 are provided.
A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
A61P 11/00 - Drugs for disorders of the respiratory system
C07K 16/18 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans
C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
74.
SCALABLE FABRICATION OF A SELF-ASSEMBLED CELL SHEET AND USES THEREOF
This disclosure relates to methods of fabricating self-assembled 3D cell sheets. In one embodiment, the cell sheets are formed by seeding cells to a monolayer density of at least 65% with a culture medium on to a substantially flat substrate having low surface energy and incubating cells on the substrate under time and temperature conditions to form a cell sheet.
A61K 31/397 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
A61K 31/4025 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
A61K 31/496 - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
A61K 31/7088 - Compounds having three or more nucleosides or nucleotides
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
A61P 35/04 - Antineoplastic agents specific for metastasis
C07D 307/88 - Benzo [c] furansHydrogenated benzo [c] furans with one oxygen atom directly attached in position 1 or 3
C07D 405/12 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
The disclosure relates to the design and preparation of a luminescent polymer film and in particular, to improve the efficiency of photovoltaic (PV) cells under diffuse lighting conditions and methods of making and uses thereof.
H01L 31/055 - Optical elements directly associated or integrated with the PV cell, e.g. light-reflecting means or light-concentrating means where light is absorbed and re-emitted at a different wavelength by the optical element directly associated or integrated with the PV cell, e.g. by using luminescent material, fluorescent concentrators or up-conversion arrangements
78.
COMPOSITION AND METHOD FOR BACTERIOPHAGE SUSCEPTIBILITY SCREENING
A composition comprises a sugar-based matrix, wherein the sugar-based matrix encapsulates a phage and a reagent for detecting a bacterial cell condition. In aspects, the bacterial cell condition is cell growth, cell metabolic activity, cell death, cell membrane integrity, cell lysis, or any combination thereof. Related screening platforms, libraries, and methods are also described.
C12Q 1/70 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving virus or bacteriophage
C12N 7/00 - Viruses, e.g. bacteriophagesCompositions thereofPreparation or purification thereof
C12N 11/10 - Enzymes or microbial cells immobilised on or in an organic carrier the carrier being a carbohydrate
C12Q 1/02 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving viable microorganisms
C40B 30/06 - Methods of screening libraries by measuring effects on living organisms, tissues or cells
G01N 33/52 - Use of compounds or compositions for colorimetric, spectrophotometric or fluorometric investigation, e.g. use of reagent paper
79.
COMPOSITION AND METHOD FOR BACTERIOPHAGE SUSCEPTIBILITY SCREENING
C12N 11/10 - Enzymes or microbial cells immobilised on or in an organic carrier the carrier being a carbohydrate
C12Q 1/02 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving viable microorganisms
C12Q 1/70 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving virus or bacteriophage
C40B 30/06 - Methods of screening libraries by measuring effects on living organisms, tissues or cells
G01N 33/52 - Use of compounds or compositions for colorimetric, spectrophotometric or fluorometric investigation, e.g. use of reagent paper
80.
A DOPPLER-BASED NON-INVASIVE COMPUTATIONAL DIAGNOSTIC METHOD FOR PERSONALIZED CARDIOLOGY
Described is a Doppler-based non-invasive computational diagnostic method for personalized cardiology of subjects (e.g., patients with valvular diseases in both pre and post intervention status). The method may be performed for determining dynamic behavior of an aortic valve of the subject, the aortic valve having multiple asymmetric valve leaflets. The method includes receiving Doppler echocardiography images of the subject; processing the received images to reconstruct a 3D geometry of the valve leaflets; determining transient pressure boundary conditions for the valve leaflets using a lumped parameter model specific to the subject; performing a first finite element simulation to determine one or more geometrical parameters for the valve leaflets; iteratively calibrating initial value of one or more material parameters for the subject; and performing a second finite element simulation, based on the calibrated one or more material parameters, to determine an indicator of the dynamic behavior of the aortic valve.
The present application relates to inosine monophosphate dehydrogenase (IMPDH) inhibitors for treating or preventing brain metastasis of a cancer For example, the IMPDH inhibitors are compounds of Formula I.
A61K 31/397 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
A61K 31/496 - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
A61K 31/4025 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
A61P 35/04 - Antineoplastic agents specific for metastasis
C07D 307/88 - Benzo [c] furansHydrogenated benzo [c] furans with one oxygen atom directly attached in position 1 or 3
C07D 405/12 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
A61K 31/7088 - Compounds having three or more nucleosides or nucleotides
C12Q 1/00 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions
83.
Hydrogel Microstructure Arrays, Methods of Making and Uses Thereof
This disclosure relates to a hydrogel comprising a crosslinked biomolecule, wherein the hydrogel comprises microscale structures. Also described is a hydrogel comprising an ordered array of semi-spherical microbumps, wherein the hydrogel is bacteria-repellent. Also described is a hierarchically-structured protein hydrogel that inhibits long term attachment of multidrug resistant Staphylococcus aureus up to 100× over a flat hydrogel. Methods of making and uses thereof are also disclosed herein.
B29C 41/00 - Shaping by coating a mould, core or other substrate, i.e. by depositing material and stripping-off the shaped articleApparatus therefor
B29C 41/02 - Shaping by coating a mould, core or other substrate, i.e. by depositing material and stripping-off the shaped articleApparatus therefor for making articles of definite length, i.e. discrete articles
Described herein is a pumpless recirculating platform for substantially unidirectional fluid flow. Also described herein is an epithelium model with patterned crypts and underlying perfusable microvasculature. A stamp for imprinting a patterned crypt on a crosslinked hydrogel scaffold is also described as well as an open chamber for cell culture, the chamber comprising a basolaterally perfused compartment and an apically perfused compartment. Related systems and methods are also described.
C12N 5/078 - Cells from blood or from the immune system
C12Q 1/00 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions
An optical grating comprising a refractive index with a periodic pattern that includes a base period Λ0; a periodic sampling of the base period, with a first period Λ1 and a first duty cycle p1, thereby defining a single-sampled grating (SSG); and a periodic sampling of the SSG, with a second period Λ2 and a second duty cycle p2. The resulting dual-sampled grating (DSG) can have a reflection spectrum containing reflection peaks. If two DSGs having different reflection spectra share a common interface, a tunable optical filter can be produced, where electrical or heating means can cause a reflection peak of one spectrum to be shifted to coincide with a reflection peak of the other spectrum, thereby filtering the corresponding wavelength. By inserting between the two DSGs a gain medium and a phase-tuning medium, a laser source structure is realized. Either device can be produced by etching or stacking methods.
H01S 5/183 - Surface-emitting [SE] lasers, e.g. having both horizontal and vertical cavities having only vertical cavities, e.g. vertical cavity surface-emitting lasers [VCSEL]
H01S 5/062 - Arrangements for controlling the laser output parameters, e.g. by operating on the active medium by varying the potential of the electrodes
86.
Anti-DFS70 Autoantibodies and methods of attenuating formation of nets
A method of attenuating the formation of neutrophil extracellular traps (NETs) in a mammal is provided comprising administering to the mammal a therapeutically effective amount of DFS70 autoantibody, a functionally equivalent variant thereof or nucleic acid encoding DFS70 antibody.
This disclosure relates to methods of making omniphobic materials which are physically and chemically modified at their surface to create hierarchically structured materials with both nanoscale and microscale structures that provide the omniphobic properties. Uses thereof, including as flexible tubular structures that repel contaminants are also disclosed herein.
B05D 1/00 - Processes for applying liquids or other fluent materials
B05D 5/08 - Processes for applying liquids or other fluent materials to surfaces to obtain special surface effects, finishes or structures to obtain an anti-friction or anti-adhesive surface
A61K 31/536 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and at least one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with carbocyclic ring systems
A61K 31/537 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and at least one oxygen as the ring hetero atoms, e.g. 1,2-oxazines spiro-condensed or forming part of bridged ring systems
This application relates to omniphobic materials which are physically and chemically modified at their surface to create hierarchically structured materials with both nanoscale and microscale structures that provide the omniphobic properties. Methods of making such omniphobic surfaces with hierarchical structures and uses thereof, including as flexible films that repel contaminants are also disclosed in the application.
B05D 5/08 - Processes for applying liquids or other fluent materials to surfaces to obtain special surface effects, finishes or structures to obtain an anti-friction or anti-adhesive surface
B05D 3/02 - Pretreatment of surfaces to which liquids or other fluent materials are to be appliedAfter-treatment of applied coatings, e.g. intermediate treating of an applied coating preparatory to subsequent applications of liquids or other fluent materials by baking
B05D 3/06 - Pretreatment of surfaces to which liquids or other fluent materials are to be appliedAfter-treatment of applied coatings, e.g. intermediate treating of an applied coating preparatory to subsequent applications of liquids or other fluent materials by exposure to radiation
This disclosure relates to catalytic nucleic acids, catalytic nucleic acid probes, biosensors, and kits for detecting the presence of Clostridium difficile. Also provided are methods for detecting the presence of Clostridium difficile in a test sample, using the catalytic nucleic acids, catalytic nucleic acid probes, biosensors, and kits.
C12Q 1/689 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for bacteria
C12Q 1/6818 - Hybridisation assays characterised by the detection means involving interaction of two or more labels, e.g. resonant energy transfer
91.
METHOD AND SYSTEM FOR DETERMINING INDIVIDUALIZED HEAD RELATED TRANSFER FUNCTIONS
There is provided a system and method for determining individualized head related transfer functions (HRTF) for a user. The method including: receiving measurement data from the user, the measurement data generated by repeatedly emitting an audible reference sound at positions in space around the user and, during each emission, recording sounds received near each ear of the user, the measurement data including, for each emission, the recorded sounds and positional information of the emission; determining the individualized HRTF by updating a decoder of a trained generative artificial neural network model, the decoder receives the measurement data as input, the trained generative artificial neural network model including an encoder and the decoder, the generative artificial neural network model is trained using data gathered from a plurality of test subjects with known spectral representations and directions for associated HRTFs at different positions in space; and outputting the individualized HRTF.
This disclosure relates to superhydrophobic materials and/or surfaces comprising a shrinkable polymer substrate and at least one polysiloxane layer, wherein the materials and/or surfaces comprise microscale wrinkles and nanoscale features that form hierarchical structures. Methods of making and uses thereof are also disclosed herein.
B05D 3/14 - Pretreatment of surfaces to which liquids or other fluent materials are to be appliedAfter-treatment of applied coatings, e.g. intermediate treating of an applied coating preparatory to subsequent applications of liquids or other fluent materials by electrical means
B05D 5/06 - Processes for applying liquids or other fluent materials to surfaces to obtain special surface effects, finishes or structures to obtain multicolour or other optical effects
C08J 7/06 - Coating with compositions not containing macromolecular substances
C09D 5/14 - Paints containing biocides, e.g. fungicides, insecticides or pesticides
TOYOTA MOTOR ENGINEERING & MANUFACTURING NORTH AMERICA, INC. (USA)
TOYOTA JIDOSHA KABUSHIKI KAISHA (Japan)
McMaster University (Canada)
Inventor
Farid, Yashar Zeiynali
Yang, Hao
Ucar, Seyhan
Oguchi, Kentaro
Abstract
An example operation includes one or more of receiving traffic data from a plurality of transports that are currently in operation within a predetermined geographic area, partitioning a map of the predetermined geographic area into a plurality of partitions based on link states within the traffic data, generating a plurality of macroscopic fundamental diagrams (MFDs) for the plurality of partitions based on flow rates and link densities in the traffic data, and mitigating congestion within the predetermined geographic area based on the plurality of MFDs for the plurality of partitions.
TOYOTA MOTOR ENGINEERING & MANUFACTURING NORTH AMERICA, INC. (USA)
TOYOTA JIDOSHA KABUSHIKI KAISHA (Japan)
McMaster University (Canada)
Inventor
Farid, Yashar Zeiynali
Yang, Hao
Ucar, Seyhan
Oguchi, Kentaro
Abstract
An example operation includes one or more of receiving traffic data uploaded from vehicles that are currently operating within a geographic area via a computer network, generating a plurality of macroscopic fundamental diagrams (MFDs) for a plurality of sub-areas within the geographic area, respectively, based on the received traffic data, identifying a sub-area among the plurality of sub-areas which is congested based on the plurality of MFDs, and transmitting routing instructions to the vehicles within the geographic area to divert the vehicles away from the sub-area.
The present application describes process for preparing an ortho-allylated hydroxy aryl compounds such as compounds of Formula (I) by reacting an allylic alcohol with a hydroxy aryl compound in the presence of aluminum compound selected from alumina and aluminum alkoxides and in a non-protic solvent wherein at least one carbon atom ortho to the hydroxy group in the hydroxy aryl compound is unsubstituted.
The present application describes process for preparing an ortho-allylated hydroxy aryl compounds such as compounds of Formula (I) by reacting an allylic alcohol with a hydroxy aryl compound in the presence of aluminum compound selected from alumina and aluminum alkoxides and in a non-protic solvent wherein at least one carbon atom ortho to the hydroxy group in the hydroxy aryl compound is unsubstituted.
C07C 37/16 - Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom of a six-membered aromatic ring by reactions increasing the number of carbon atoms by condensation involving hydroxy groups of phenols or alcohols or the ether or mineral ester group derived therefrom
A method of detecting the expression level of miRNA markers in a biological sample obtained from a mammal is provided. The method incudes the steps of i) detecting the expression level of one or more miRNA markers selected from the group of miR-199a-3p, miR-143-3p, miR-340-5p, let-7b-5p, miR-21-5p, miR-17-5p, miR-20a-5p and miR-103a-3p, in the biological sample; ii) detecting the expression level of at least one miRNA reference marker selected from miR-148b-3p and miR-30e-5p in the biological sample; and iii) normalizing the expression level of the miRNA marker(s) against the expression level of the miRNA reference marker in the sample and in a control. The method is useful for the diagnosis of endometriosis, monitoring of patient response to treatment, and assessment of disease progression and/or severity.
A co-planar transformer is provided. A dual-active bridge converter comprising the co-planar transformer is also provided. The co-planar transformer comprises a printed circuit board with a plurality of primary windings and a plurality of secondary windings. The number of primary winding turns is equal to the number of secondary winding turns. The plurality of primary windings and the plurality of secondary windings are provided on the same printed circuit board in an interleaving configuration, wherein the interleaving is provided horizontally across the printed circuit board. Other embodiments of co-planar transformers include two or more such printed circuit boards with interleaved plurality of primary and secondary windings.
H02M 3/335 - Conversion of DC power input into DC power output with intermediate conversion into AC by static converters using discharge tubes with control electrode or semiconductor devices with control electrode to produce the intermediate AC using devices of a triode or a transistor type requiring continuous application of a control signal using semiconductor devices only
H05K 1/14 - Structural association of two or more printed circuits
An LLC resonant converter is provided. The LLC resonant converter includes a primary sub-circuit coupled to a direct-current (DC) input voltage and a first secondary sub-circuit and a second secondary sub-circuit. The primary sub-circuit includes a resonant tank, that includes a combination of a resonant inductor, a resonant capacitor and a magnetizing inductor. The LLC resonant converter also includes a first transformer isolating the primary sub-circuit from the first secondary sub-circuit and a second transformer isolating the primary sub-circuit from the second secondary sub-circuit. The first and the second secondary sub-circuits are configurable in a series mode and a parallel mode by switching configurations of a plurality of transition switches, and the first and the second secondary sub-circuits provide an output charging voltage and an output charging current for charging an external device. A charging station comprising one or more charging poles, with each charging pole comprising one of more LLC resonant converter modules is also disclosed.
B60L 53/62 - Monitoring or controlling charging stations in response to charging parameters, e.g. current, voltage or electrical charge
H02J 7/00 - Circuit arrangements for charging or depolarising batteries or for supplying loads from batteries
H02J 50/12 - Circuit arrangements or systems for wireless supply or distribution of electric power using inductive coupling of the resonant type
H02J 50/40 - Circuit arrangements or systems for wireless supply or distribution of electric power using two or more transmitting or receiving devices
H02M 3/00 - Conversion of DC power input into DC power output
H02M 3/335 - Conversion of DC power input into DC power output with intermediate conversion into AC by static converters using discharge tubes with control electrode or semiconductor devices with control electrode to produce the intermediate AC using devices of a triode or a transistor type requiring continuous application of a control signal using semiconductor devices only
99.
SYSTEMS, METHODS, AND COMPUTER PROGRAM PRODUCTS FOR EVALUATING MACHINE LEARNING MODEL PERFORMANCE
A system, method and computer program product for evaluating a multi-label classification machine learning model. A model labelled dataset is received from the model and includes a plurality of data elements each labelled with zero or more model predicted labels of q potential classes. A multi-label confusion matrix is defined to include q+1 rows with q rows for true labels and 1 row for no true label and q+1 columns with q columns for predicted labels and 1 column for no predicted label. The matrix is populated by comparing the model labelled dataset with a true labelled dataset. At least one performance metric is calculated from the populated multi-label confusion matrix.
The present application is directed to methods of performing chemical reactions, including multi-step chemical reactions in which two or more of the reagents in the chemical reaction are incorporated or entrapped in a solid polymeric structure comprising pullulan. In certain embodiments, the chemical reaction or multi-step reaction serves as a sensor. Accordingly the present application is also directed to sensors for performing the methods of the application. In certain embodiments, at least one of the reagents is a biomolecule and the sensor is a biosensor. In certain other embodiments, the solid polymeric structure comprising pullulan and the reagents for performing a chemical reaction form a convenient device for performing a chemical reaction.
G01N 33/543 - ImmunoassayBiospecific binding assayMaterials therefor with an insoluble carrier for immobilising immunochemicals
C12Q 1/66 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving luciferase
G01N 21/77 - Systems in which material is subjected to a chemical reaction, the progress or the result of the reaction being investigated by observing the effect on a chemical indicator
G01N 21/78 - Systems in which material is subjected to a chemical reaction, the progress or the result of the reaction being investigated by observing the effect on a chemical indicator producing a change of colour
